Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: Role of Trp112 (Trp111)

FEBS Letters

Volumn 587, Issue 22, 2013, Pages 3681-3686

  Zhang, Liping ^a   Zhang, Hong ^a   Zhao, Yining ^a   Li, Zhe ^a   Chen, Shangke ^a   Zhai, Jing ^a   Chen, Yunyun ^a   Xie, Wei ^a   Wang, Zhong ^a   Li, Qing ^a   Zheng, Xuehua ^a   Hu, Xiaopeng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

AKR1B1; AKR1B10; Crystal structure; Inhibitor selectivity

Indexed keywords

ALDEHYDE REDUCTASE; ALDO KETO REDUCTASE FAMILY MEMBER 1B1; ALDO KETO REDUCTASE FAMILY MEMBER 1B10; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; FIDARESTAT; FLUFENAMIC ACID; GLUTAMINE; OLEANOLIC ACID; SORBINIL; TOLRESTAT; TRYPTOPHAN; UNCLASSIFIED DRUG; ZOPOLRESTAT;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; HYDROGEN BOND; PRIORITY JOURNAL; STRUCTURAL HOMOLOGY;

AKR1A1; AKR1B1; AKR1B10; ALDEHYDE REDUCTASE; ALDO-KETO REDUCTASE FAMILY1 MEMBER10; ALDOSE REDUCTASE ALDO-KETO REDUCTASE FAMILY1 MEMBER1; CRYSTAL STRUCTURE; FLF; FLUFENAMIC ACID; INHIBITOR SELECTIVITY;

ALDEHYDE REDUCTASE; BENZOTHIAZOLES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FLUFENAMIC ACID; HYDROGEN BONDING; IMIDAZOLIDINES; MODELS, MOLECULAR; NAPHTHALENES; OLEANOLIC ACID; PHTHALAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RHODANINE; STRUCTURAL HOMOLOGY, PROTEIN; THIAZOLIDINES; TRYPTOPHAN;

EID: 84887409478     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.09.031     Document Type: Article

References (29)

1. R.D. Mindnich, and T.M. Penning Aldo-keto reductase (AKR) superfamily: genomics and annotation Human Genomics 3 2009 362 370
2. T.M. Penning, and J.E. Drury Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms Arch. Biochem. Biophys. 464 2007 241 250
3. J.M. Petrash All in the family: aldose reductase and closely related aldo-keto reductases Cell. Mol. Life Sci. 61 2004 737 749
4. E. Pastel, J.C. Pointud, F. Volat, A. Martinez, and A.M. Lefrancois-Martinez Aldo-keto reductases 1b in endocrinology and metabolism Front. Pharm. 3 2012 148
5. D. Cao, S.T. Fan, and S.S.M. Chung Identification and characterization of a novel human aldose reductase-like gene J. Biol. Chem. 273 1998 11429 11435
6. S. Kapoor AKR1B10 and its emerging role in tumor carcinogenesis andas a cancer biomarker Int. J. Cancer 132 2013 495
7. O. Gallego Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10 Proc. Natl. Acad. Sci. U.S.A. 104 2007 20764 20769
8. C. Wang, R. Yan, D. Luo, K. Watabe, D.F. Liao, and D. Cao Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls J. Biol. Chem. 284 2009 26742 26748
9. T. Matsunaga, Y. Yamane, K. Iida, S. Endo, Y. Banno, O. El-Kabbani, and A. Hara Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms Anti-cancer Drugs 22 2011 402 408
10. M. Takemura Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid J. Nat. Prod. 74 2011 1201 1206
11. M. Soda Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10 Eur. J. Med. Chem. 48 2012 321 329
12. S. Endo, T. Matsunaga, M. Soda, K. Tajima, H.T. Zhao, O. El-Kabbani, and A. Hara Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid Biol. Pharm. Bull. 33 2010 886 890
13. T. Matsunaga, S. Endo, M. Soda, H.T. Zhao, O. El-Kabbani, K. Tajima, and A. Hara Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis Biochem. Biophys. Res. Commun. 389 2009 128 132
14. F.X. Ruiz, A. Cousido-Siah, A. Mitschler, J. Farres, X. Pares, and A. Podjarny X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity Chemico-Biol. Interact. 202 2013 178 185
15. X. Zheng, L. Zhang, J. Zhai, Y. Chen, H. Luo, and X. Hu The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase FEBS Lett. 586 2012 55 59
16. Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography Acta Crystallogr. Section D: Biol. Crystallogr. 50 1994 760 763
17. P.D. Adams PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. Section D: Biol. Crystallogr. 66 2010 213 221
18. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. Section D: Biol. Crystallogr. 60 2004 2126 2132
19. K. Sundaram, U. Dhagat, S. Endo, R. Chung, T. Matsunaga, A. Hara, and O. El-Kabbani Structure of rat aldose reductase-like protein AKR1B14 holoenzyme: Probing the role of His269 in coenzyme binding by site-directed mutagenesis Bioorg. Med. Chem. Lett. 21 2011 801 804
20. J. Liu, D.H. Dyer, J. Cheng, J. Wang, S. Wang, Z. Yang, X. Wang, and W. Hu Aldose reductase from Schistosoma japonicum: crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds Parasit. Vectors 6 2013 162
21. D.K. Wilson, T. Nakano, J.M. Petrash, and F.A. Quiocho 1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor Biochemistry 34 1995 14323 14330
22. Q. Ye, D. Hyndman, X. Li, T.G. Flynn, and Z. Jia Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily Proteins 38 2000 41 48
23. A. Urzhumtsev A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil Structure 5 1997 601 612
24. D.K. Wilson, I. Tarle, J.M. Petrash, and F.A. Quiocho Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat Proc. Natl. Acad. Sci. U.S.A. 90 1993 9847 9851
25. M. Oka, Y. Matsumoto, S. Sugiyama, N. Tsuruta, and M. Matsushima A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′- dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography J. Med. Chem. 43 2000 2479 2483
26. O. El-Kabbani Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors Proteins 55 2004 805 813
27. S. Endo, T. Matsunaga, K. Kuwata, H.T. Zhao, O. El-Kabbani, Y. Kitade, and A. Hara Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10 Bioorg. Med. Chem. 18 2010 2485 2490
28. S. Endo Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids Arch. Biochem. Biophys. 487 2009 1 9
29. M. Soda, S. Endo, T. Matsunaga, H.T. Zhao, O. El-Kabbani, M. Iinuma, K. Yamamura, and A. Hara Inhibition of human aldose reductase-like protein (AKR1B10) by alpha- and gamma-mangostins, major components of pericarps of mangosteen Biol. Pharm. Bull. 35 2012 2075 2080